News

Cilostazol Matches Double-Dose Clopidogrel Following PCI


 

FROM THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dr. Kim said he had no relevant financial disclosures. Dr. Ohman said that he has been a consultant to a wide variety of pharmaceutical companies, including Sanofi-Aventis, Merck, Bristol-Myers Squibb, AstraZeneca, and Boehringer Ingelheim. He has received research support from Eli Lilly, Maquet, and Daiichi Sankyo. Dr. Stone said that he has also been a consultant to a variety of pharmaceutical companies. Dr. Dangas said that he has been a consultant to AstraZeneca and has received research grants from Sanofi-Aventis, Bristol-Myers Squibb, Eli Lilly, and Daiichi Sankyo.

Pages

Recommended Reading

Infections, Pulmonary Complications Up Risk of Thrombotic Events
MDedge Cardiology
Cardiac Surgical Transfusions Linked to Infection Risk
MDedge Cardiology
IVC Filter Perforations Are Often Asymptomatic
MDedge Cardiology
CAS, CEA Evaluated for Contralateral Occlusion
MDedge Cardiology
Everlolimus-Eluting Coronary Stents Notch Major Thrombosis Victory
MDedge Cardiology
CoreValve Excels in 'Real-World' Study
MDedge Cardiology
Four Common Comorbidities Hike Risk of Late Post-TAVI Death
MDedge Cardiology
Prasugrel Bests Double-Dose Clopidogrel in Clopidogrel Nonresponders
MDedge Cardiology
Elective Angioplasty Safe at Hospitals Without Surgical Backup
MDedge Cardiology
Intracoronary Abciximab Reduces Size of Large Myocardial Infarcts
MDedge Cardiology